Programmable immunity, engineered T cell therapies, early disease detection
Human health has been transformed by our collective capacity to engineer immunity – from the pivotal development of the smallpox vaccine to the curative potential of recent cancer immunotherapies. These examples motivate our research program that is conducted at the interface of Engineering and Immunology, and where we develop biomedical technologies and applications that shape a diverse array of immunological systems.
The questions that are central to our exploration include: How do we begin to study an individual's repertoire of well over one billion immune cells when current technologies only allow us to study a handful of cells at a time? What are the biomarkers of immunological health as the body responds to disease and ageing, and how may these indicators trigger clinical decisions? And how can we genetically rewire immune cells to provide them with entirely new functions to better fight complex diseases such as cancer?
To aid in our studies, we use high-throughput technologies such as next-generation sequencing and quantitative mass spectrometry, and pioneer the development of micro- and nanotechnologies in order to achieve our goals. We focus on clinical problems in cancer, infectious diseases and autoimmunity, and ultimately strive to translate key findings into therapies for patients.